What is Microbot Medical's stock issuance costs payable?

Microbot Medical (MBOT) reported stock issuance costs payable of $153K in Q3 2025.

What does stock issuance costs payable mean?

The amount of stock issuance costs that have been incurred but remain unpaid at the end of the reporting period. This represents a short-term liability associated with equity financing activities.

Microbot Medical MBOT Stock Issuance Costs Payable

Stock Issuance Costs Payable at other companies

Beta Technologies BETA

$195K-97.9%

CG OncologyCGON

$139K-35.3%

4D Molecular TherapeuticsFDMT

$76.75K—

QT Imaging Holdings, Inc.QTI

$74K—

SCP

Social Commerce Partners Corporation SCPQ

$279.1K—

Artiva Biotherapeutics, Inc.ARTV

$0-100%

Other financials

Income statement

See full

Revenue$105.0K—

Gross profit$2.0K—

Operating income-$4.3M-43.0%

Net income-$3.7M-41.1%

EPS (diluted)-$0.05+37.5%

Balance sheet

See full

Cash & equivalents$3.7M+13.7%

Total debt$898.0K+551%

Total equity$74.1M+156%

Total assets$78.1M+153%

Cash flow

See full

Operating cash flow-$5.1M-75.8%

CapEx$108.0K+731%

Free cash flow-$5.2M-78.8%

Valuation

See full

Market cap$128.28M+36.1%

Enterprise value$125.53M+39.0%

P/S674.3×—

Profitability

See full

Operating margin25,292.9%—

Net margin-3,669.9%—

FCF margin-852.8%—

Returns & leverage

See full

Return on equity-27.6%-10.2pp

Debt / equity0×0.0×

Current ratio22.6×+6.4×

Where this comes from

Reported directly by Microbot Medical in its filing.

Tagged under the XBRL concept MBOT:StockIssuanceCostsPayable.

The official record: Microbot Medical’s 10-Q, filed November 12, 2025, on SEC EDGAR. View the filing →

Ask your AI about Microbot Medical's stock issuance costs payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Microbot Medical's stock issuance costs payable?: Microbot Medical (MBOT) reported stock issuance costs payable of $153K in Q3 2025.
What does stock issuance costs payable mean?: The amount of stock issuance costs that have been incurred but remain unpaid at the end of the reporting period. This represents a short-term liability associated with equity financing activities.